This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| DME | |
|---|---|
| Name | DME |
| Field | Ophthalmology |
DME
Diabetic macular edema (DME) is a retinal complication of chronic hyperglycemia that produces macular thickening and visual impairment. It commonly arises in the context of long-standing metabolic dysregulation and microvascular injury, and it is managed by multimodal medical, surgical, and interventional approaches. Clinical recognition, timely imaging, and coordination among specialists inform outcomes and public health strategies.
DME denotes retinal swelling involving the macula associated with diabetes mellitus and is described using structural and functional terms drawn from ophthalmic practice. Classification schemes reference focal, diffuse, cystoid, and ischemic patterns and incorporate staging systems from clinical trials and consensus guidelines. Major terminological frameworks appear alongside entities such as proliferative diabetic retinopathy and nonproliferative diabetic retinopathy in documents from organizations like the American Academy of Ophthalmology, Royal College of Ophthalmologists, World Health Organization, International Council of Ophthalmology, and professional registries.
DME occurs as a consequence of chronic hyperglycemia and its metabolic sequelae; key risk factors identified in cohort and randomized studies include duration of diabetes, poor glycemic control, and hypertension. Other important associations appear in literature referencing Type 1 diabetes mellitus, Type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, and systemic inflammation. Demographic and comorbidity correlates have been reported in cohorts from institutions such as Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Karolinska Institutet, and registries like UK Biobank.
Pathophysiology integrates microvascular dysfunction, inflammation, and neurodegeneration. Hyperglycemia-driven pathways—advanced glycation end-products, protein kinase C activation, polyol flux—contribute to pericyte loss, basement membrane thickening, and endothelial dysfunction. Breakdown of the inner blood–retinal barrier permits plasma leakage into the macula; vascular endothelial growth factor (VEGF) and inflammatory mediators such as interleukins and tumor necrosis factor are central. Evidence from basic science and translational studies links these processes to findings reported by research groups at National Institutes of Health, Diabetes Control and Complications Trial, United Kingdom Prospective Diabetes Study, European Eye Epidemiology Consortium, and academic centers like Stanford University, Harvard Medical School, and University of Oxford.
Diagnosis is based on symptoms, clinical examination, and multimodal imaging. Visual acuity testing, slit-lamp fundus examination, and optical coherence tomography (OCT) establish macular thickness and cystic changes; fluorescein angiography characterizes leakage and ischemia. Screening programs are implemented by health systems and agencies including NHS England, Centers for Disease Control and Prevention, Australian Diabetes Society, and specialist networks; protocols often derive from trials and guidelines produced by entities such as the American Diabetes Association and the European Society of Retina Specialists. Telemedicine platforms, artificial intelligence algorithms developed at institutions like Google DeepMind, Massachusetts Institute of Technology, and collaborations with vendors are increasingly used for population screening.
Management combines systemic risk modification, intravitreal pharmacotherapy, laser, and surgery when indicated. Intravitreal anti-VEGF agents (bevacizumab, ranibizumab, aflibercept) are first-line in many randomized controlled trials led by groups at Basel University Hospital, University College London, Cleveland Clinic, and industry-sponsored consortia. Corticosteroid implants and injections (dexamethasone, fluocinolone) are alternatives for refractory or pseudophakic eyes, with evidence from trials associated with sponsors and centers such as Novartis, Allergan, Vanderbilt University Medical Center, and Duke University Medical Center. Focal/grid laser photocoagulation remains a tool in select cases per historical trials like those from the Early Treatment Diabetic Retinopathy Study. Vitrectomy is considered for tractional components and is performed in tertiary centers including Wills Eye Hospital and Bascom Palmer Eye Institute.
Prognosis varies with promptness of treatment, baseline visual acuity, and control of systemic factors. Complications of untreated or progressive DME include persistent vision loss, macular ischemia, and development of secondary complications requiring complex care in referral centers. Treatment carries procedure-specific risks such as endophthalmitis, intraocular pressure elevation, cataract progression, and rare systemic events; safety and long-term outcomes have been characterized in longitudinal studies by groups at Cedars-Sinai Medical Center, Karolinska University Hospital, and multicenter trial networks.
DME prevalence mirrors diabetes prevalence and demographic shifts; global estimates derive from population studies in regions represented by cohorts in China, India, United States, United Kingdom, and Europe. Rising incidence in aging and urbanizing populations poses challenges for screening and resource allocation considered by policymakers at World Health Organization, United Nations, and national health ministries. Economic analyses and health-service research published by institutions such as University of Toronto, Harvard T.H. Chan School of Public Health, and Imperial College London inform cost-effectiveness of screening, anti-VEGF therapy deployment, and integrated diabetes care models.
Category:Retinal diseases